Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

927.00 +11.96 (+1.31%)
Streaming Delayed Price Updated: 2:55 PM EDT, Sep 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,909,775
Open 921.99
Bid (Size) 926.73 (2)
Ask (Size) 927.26 (2)
Prev. Close 915.04
Today's Range 913.20 - 939.86
52wk Range 516.57 - 972.53
Shares Outstanding N/A
Dividend Yield 0.49%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
In-Depth Analysis: Eli Lilly Versus Competitors In Pharmaceuticals Industry
Via Benzinga
Eli Lilly Fights $183M Medicaid Fraud Judgment, Cites Reasonable Interpretation Of Medicaid Rules
Eli Lilly appeals a $183 million judgment in a Medicaid fraud case, arguing that it followed a reasonable interpretation of the law. The case has drawn attention from major business and pharmaceutical... 
Via Benzinga
Topics Fraud
Exposures Legal

Performance

YTD
+56.53%
+56.53%
1 Month
-2.42%
-2.42%
3 Month
+4.63%
+4.63%
6 Month
+20.35%
+20.35%
1 Year
+62.73%
+62.73%

More News

Read More
Why Tandem Diabetes Care Stock Thrashed the Market Today
Via The Motley Fool
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
Via Investor's Business Daily
1 Unstoppable Stock That Could Join the $1 Trillion Club in 2025
Via The Motley Fool
Looking Into Eli Lilly's Recent Short Interest
Via Benzinga
Unpacking the Latest Options Trading Trends in Eli Lilly
Via Benzinga
6 Incredible Reasons to Invest in Eli Lilly
Via The Motley Fool
Looking At Eli Lilly's Recent Unusual Options Activity
Via Benzinga
Prediction: This Will be Eli Lilly's Next Big Move.
Via The Motley Fool
Why ResMed Stock Tumbled by 5% Today
Via The Motley Fool
This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments
Via The Motley Fool
ADX: A High-Yielding, Diversified CEF Worth Looking Into
Via Talk Markets
Prediction: This Will Be the First Healthcare Stock to Join the Trillion-Dollar Club
Via The Motley Fool
Unpacking the Latest Options Trading Trends in Eli Lilly
Via Benzinga
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
Via The Motley Fool
Eli Lilly Scores FDA Approval For Eczema Treatment Ebglyss
Via Benzinga
Exposures Product Safety
Kalm Therapeutics Hires Former GSK Director Dr. Tomoko Maeda-Chubachi as Chief Medical Officer
Via Newsfile
3 Stocks to Buy and Hold Forever
Via The Motley Fool
Time To Invest And Or Trade In Bio-Tech Stocks?
Via Talk Markets
Topics ETFs
Stock Market Rally Revives; Apple iPhone 16, Nvidia, Oracle, Adobe In Focus: Weekly Review
Via Investor's Business Daily
Eli Lilly Pumps $800M Into Irish Operations To Meet Skyrocketing Demand For Mounjaro, Zepbound
Via Benzinga
Forget Eli Lilly and Novo Nordisk: This Could Be the Best Weight Loss Stock to Buy Right Now
Via The Motley Fool
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
Via The Motley Fool
Why Roche Holdings Stock Withered on Wednesday
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.